NEW YORK, NY.

Pfizer is voluntarily recalling five (5) lots of Accupril (Quinapril HCl) tablets distributed by Pfizer to the patient (consumer/user) level due to the presence of a nitrosamine, N-nitroso-quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level. 

Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables. Everyone is exposed to some level of nitrosamines. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time^.i 

Accupril is indicated for the treatment of hypertension, to lower blood pressure.  Accupril is also indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics and/or digitalis. Accupril has a safety profile that has been established over 30 years. To date, Pfizer is not aware of reports of adverse events that have been assessed to be related to this recall. Pfizer believes the benefit/risk profile of the products remains positive based on currently available data. Although long-term ingestion of N-nitroso-quinapril may be associated with a potential increased cancer risk in humans, there is no immediate risk to patients taking this medication. Patients currently taking the products should consult with their doctor or health care provider about alternative treatment options for them.

The NDC, Lot Number, Expiration Date, and Configuration details for these products are indicated in the tables below and photos of the products can be found at the end of this press release. The product lots were distributed nationwide to wholesalers and distributors in the United States and Puerto Rico from December 2019 to April 2022.

Accupril® (Quinapril HCl Tablets), 10 mg
Accupril® (Quinapril HCl Tablets), 20 mg
Accupril® (Quinapril HCl Tablets), 40 mg

Pfizer places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process. Pfizer has notified direct consignees by letter to arrange for return of any recalled product.

Wholesalers and distributors with an existing inventory of the lots, listed in the table above, should stop use and distribution and quarantine the product immediately.

If you have further distributed the recalled product, please notify any accounts or additional locations which may have received the recalled product from you. Please conduct a sub-recall to those accounts and communicate this recall information immediately. Please request they immediately cease distribution of the affected product and promptly contact Sedgwick at 888-345-0481 (Mon.-Fri.8:00 am – 5:00 pm ET) to obtain a Business Reply Form (BRF) to initiate the return process.

If you received free product through the Pfizer Patient Assistance Program (PAP) or the Pfizer Institutional Patient Assistance Program (IPAP), please check your stock immediately against the table above. If you have any of the affected product lots in your inventory, please follow the instructions above for returning the product to Sedgwick. Additionally, if you are aware of any patients to whom you dispensed the affected lots who still may have the product in their possession, please ask them to return the product to you and then follow the instructions above for returning the product to Sedgwick. To request replacement product for any Pfizer PAP or Pfizer IPAP product you return, please contact 833-203-2776 (Mon.-Fri. 8 am-6 pm ET).

Patients who are taking this product should consult with their healthcare provider or pharmacy to determine if they have the affected product. Patients with the  affected product should contact Sedgwick at 888-345-0481 (Mon.-Fri. 8:00 am – 5:00 pm ET) for instructions on how to return their product and obtain reimbursement for their cost.

Healthcare Professionals with questions regarding this recall can contact Pfizer using the below information.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

•    Complete and submit the report Online
•    Regular Mail or Fax:  Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

References: https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications

Source: Pfizer

• 
  A Healthy Lifestyle Can Offset a High Genetic Risk for Stroke, According to New Research by UTHealth Houston
  Newswise — People who are genetically at higher risk for stroke can lower that risk by as much as 43% by adopting a healthy cardiovascular lifestyle, according to new research led by UTHealth Houston, which was published today in the Journal of the American Heart Association. The study included 11,568 adults from ages 45 to 64 who… Read more: A Healthy Lifestyle Can Offset a High Genetic Risk for Stroke, According to New Research by UTHealth Houston
• Life Time Reaches 30 Years of Inspiring Health and Happiness
  From first opening in 1992 to nearly 160 athletic country clubs and more than one billion visits, countless stories of extraordinary transformation, life-altering events and strong community serve to warm the heart CHANHASSEN, Minn., July 15, 2022 /PRNewswire/ — Life Time (NYSE: LTH), the nation’s premier healthy lifestyle brand, opened its first club in a Brooklyn Park, Minn. strip mall 30… Read more: Life Time Reaches 30 Years of Inspiring Health and Happiness
• 
  Spectruth’s New Metaverse for Therapy Treatment Coming Soon.
  Ukrainian “SAFE” not-for-profit Foundation commissioned Spectruth’s development of a 3D virtual therapy metaverse.KYIV, KYIV OBLAST, UKRAINE, July 10, 2022 /EINPresswire.com/ — The future is bright for anyone seeking therapy despite lock-downs, lack of local therapists or high costs. “SAFE” Premier Therapy Clinic of Ukraine, a charitable foundation has commissioned a new 3D virtual therapy clinic… Read more: Spectruth’s New Metaverse for Therapy Treatment Coming Soon.
• 
  Aussie Company Care A2+ Gains FDA Approval to Address US Infant Formula Shortages
  Up to 4.8 million tins of premium baby formula to help address U.S. supply chain crisis SYDNEY (Newswire.com) – Care A2+, an Australian health and wellness company, today announced it has been approved by the United States Food & Drug Administration (FDA) to deliver up to 4.8 million tins of Australian-made Care A2+ Premium Infant Formula with… Read more: Aussie Company Care A2+ Gains FDA Approval to Address US Infant Formula Shortages
• 
  FDA Infant Formula Update: July 8, 2022
  Today, the U.S. Food and Drug Administration is providing an update on additional steps it has taken that will lead to more infant formula available in the U.S. under the agency’s recent increased flexibilities. Company (Product Origin): Care A2+ (Australia) Product(s): Care A2+ 0-12 Months Infant Formula Type of Formula: General Estimated Quantity: 4.875 million cans (about 8.6 million pounds… Read more: FDA Infant Formula Update: July 8, 2022